Five-year outcomes of eyes initially enrolled in the 2-year BEVORDEX trial of bevacizumab or dexamethasone implants for diabetic macular oedema.
Elisa Eleanor CornishKelvin Yi Chong TeoMark C GilliesLyndell L LimVuong NguyenSanjeewa WickremasingheHemal MehtaIan L McAllisterSamantha Fraser-BellPublished in: The British journal of ophthalmology (2021)
Eyes in the BEVORDEX trial had similar 5-year rates of cataract surgery, however, more eyes converted to PDR in the group initially treated with DEX-implant. Eyes that were initially treated for 2 years with either intravitreal DEX-implant of bevacizumab followed by standard of care had similar visual and anatomical outcomes at 5 years.
Keyphrases
- cataract surgery
- optical coherence tomography
- diabetic retinopathy
- study protocol
- soft tissue
- phase iii
- clinical trial
- healthcare
- phase ii
- palliative care
- low dose
- randomized controlled trial
- metastatic colorectal cancer
- high dose
- vascular endothelial growth factor
- pain management
- open label
- quality improvement
- adipose tissue
- newly diagnosed
- glycemic control
- insulin resistance